Latent tuberculosis infection: recent progress and challenges in South Korea
- PMID: 32131570
- PMCID: PMC7061001
- DOI: 10.3904/kjim.2020.029
Latent tuberculosis infection: recent progress and challenges in South Korea
Abstract
Management of latent tuberculosis infection (LTBI) is a critical element in the elimination of tuberculosis (TB). However, the low positive predictive value of the current diagnostic tests and the low acceptance and completion rate of the isoniazid- based regimen are major barriers to the implementation and scale-up of programmatic management of LTBI. In the past decade, there has been some progress in the conception, diagnosis, and treatment of LTBI. LTBI is now understood as a dynamic spectrum rather than the traditional binary distinction between active and latent TB. New insight into LTBI has led to a renewed interest in incipient TB, which would be a potential target for developing new diagnostics and therapeutics of LTBI. Recent studies showed that host transcriptomic signatures could be a potential biomarker for incipient TB. The new shorter rifamycin-based regimens have shown comparable efficacy, but better completion rate and safety compared to the isoniazid-based regimen. In South Korea, LTBI management has been expanded and integrated into key elements of the National Tuberculosis Control Program. For the programmatic approach to LTBI management, the following challenges need to be addressed; target group selection, treatment-related interventions, monitoring and surveillance system, and extending the plan for vulnerable groups.
Keywords: Diagnosis; Latent tuberculosis; Tuberculosis.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures


Similar articles
-
Latent tuberculosis infection: Opportunities and challenges.Respirology. 2018 Oct;23(10):893-900. doi: 10.1111/resp.13346. Epub 2018 Jun 14. Respirology. 2018. PMID: 29901251 Review.
-
Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.Respir Med. 2019 Oct;157:52-58. doi: 10.1016/j.rmed.2019.09.004. Epub 2019 Sep 9. Respir Med. 2019. PMID: 31522030
-
Analysis of nationwide adverse event reports on Isoniazid and Rifampin in tuberculosis prevention and treatment in South Korea.Sci Rep. 2025 Mar 3;15(1):7411. doi: 10.1038/s41598-025-91753-y. Sci Rep. 2025. PMID: 40032948 Free PMC article.
-
Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan.J Microbiol Immunol Infect. 2018 Dec;51(6):784-793. doi: 10.1016/j.jmii.2017.04.001. Epub 2017 Jun 29. J Microbiol Immunol Infect. 2018. PMID: 28739436
-
The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries.Expert Rev Respir Med. 2021 Jul;15(7):899-910. doi: 10.1080/17476348.2021.1862652. Epub 2021 Feb 14. Expert Rev Respir Med. 2021. PMID: 33302729 Review.
Cited by
-
The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database.J Korean Med Sci. 2022 Apr 25;37(16):e123. doi: 10.3346/jkms.2022.37.e123. J Korean Med Sci. 2022. PMID: 35470598 Free PMC article.
-
Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018.J Korean Med Sci. 2022 May 23;37(20):e164. doi: 10.3346/jkms.2022.37.e164. J Korean Med Sci. 2022. PMID: 35607742 Free PMC article.
-
TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.Int J Tuberc Lung Dis. 2021 Oct 1;25(10):823-831. doi: 10.5588/ijtld.21.0293. Int J Tuberc Lung Dis. 2021. PMID: 34615579 Free PMC article.
-
Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.J Korean Med Sci. 2021 Mar 15;36(10):e70. doi: 10.3346/jkms.2021.36.e70. J Korean Med Sci. 2021. PMID: 33724737 Free PMC article.
-
Adverse drug reactions following treatment of latent tuberculosis infection: a linked national tuberculosis surveillance with claims database.Korean J Intern Med. 2024 Nov;39(6):979-988. doi: 10.3904/kjim.2023.557. Epub 2024 Oct 22. Korean J Intern Med. 2024. PMID: 39434604 Free PMC article.
References
-
- World Health Organization . Geneva (CH): World Health Organization; 2018. Global tuberculosis report 2019 [Internet] [cited 2020 Jan 25]. Available from: https://www.who.int/tb/publications/global_report/en/
-
- Korea Centers for Disease Control and Prevention . Cheongju (KR): Korea Centers for Disease Control and Prevention; 2019. Annual report on the notified tuberculosis patients in Korea 2018 [Internet] [cited 2020 Jan 25]. Available from: http://tbzero.cdc.go.kr/tbzero/board/boardView.do.
-
- Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131–138. - PubMed
-
- Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271–286. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous